RESUMEN
Measurement of plasmalogens is useful for the biochemical diagnosis of rhizomelic chondrodysplasia punctata (RCDP) and is also informative for Zellweger spectrum disorders (ZSD). We have developed a test method for the simultaneous quantitation of C16:0, C18:0, and C018:1 plasmalogen (PG) species and their corresponding fatty acids (FAs) in dried blood spots (DBS) and erythrocytes (RBC) by using capillary gas chromatography-mass spectrometry. Normal reference ranges for measured markers and 10 calculated ratios were established by the analysis of 720 and 473 unaffected DBS and RBC samples, respectively. Determination of preliminary disease ranges was made by using 45 samples from 43 unique patients: RCDP type 1 (DBS: 1 mild, 17 severe; RBC: 1 mild, 6 severe), RCDP type 2 (DBS: 2 mild, 1 severe; RBC: 2 severe), RCDP type 3 (DBS: 1 severe), RCDP type 4 (RBC: 2 severe), and ZSD (DBS: 3 severe; RBC: 2 mild, 7 severe). Postanalytical interpretive tools in Collaborative Laboratory Integrated Reports (CLIR) were used to generate an integrated score and a likelihood of disease. In conjunction with a review of clinical phenotype, phytanic acid, and very long-chain FA test results, the CLIR analysis allowed for differentiation between RCDP and ZSD. Data will continue to be gathered to improve CLIR analysis as more samples from affected patients with variable disease severity are analyzed. The addition of DBS analysis of PGs may allow for at-home specimen collection and second-tier testing for newborn screening programs.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Trastorno Peroxisomal , Síndrome de Zellweger , Recién Nacido , Humanos , Plasmalógenos , Condrodisplasia Punctata Rizomélica/genética , Trastorno Peroxisomal/diagnóstico , Ácido FitánicoRESUMEN
Plasmalogens are glycerophospholipids characterized by a vinyl-ether bond with a fatty alcohol at the sn-1 position, a polyunsaturated fatty acid at the sn-2 position, and a polar head at the sn-3 position, commonly phosphoethanolamine. Plasmalogens play crucial roles in several cellular processes. Reduced levels have been associated with Alzheimer's and Parkinson's disease progression. Markedly reduced plasmalogens are a classic feature of peroxisome biogenesis disorders (PBD) because plasmalogen synthesis requires functional peroxisomes. Particularly, severe plasmalogen deficiency is the biochemical hallmark of rhizomelic chondrodysplasia punctata (RCDP). Traditionally, plasmalogens are evaluated in red blood cells (RBCs) by gas-chromatography/mass-spectrometry (GC-MS), which cannot distinguish individual species. We developed a liquid-chromatography/tandem mass-spectrometry (LC-MS/MS) method to quantify eighteen phosphoethanolamine plasmalogens in RBCs to diagnose PBD patients, especially RCDP. Validation results showed a specific, robust, and precise method with broad analytical range. Age-specific reference intervals were established; control medians were used to assess plasmalogen deficiency in patients' RBCs. Clinical utility was also confirmed in Pex7 deficient mouse models recapitulating severe and milder RCDP clinical phenotypes. To our knowledge, this is the first attempt to replace the GC-MS method in the clinical laboratory. In addition to diagnosing PBDs, structure-specific plasmalogen quantitation could help understand disease pathogenesis and monitor therapy.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Plasmalógenos , Ratones , Animales , Cromatografía Liquida , Espectrometría de Masas en Tándem , Condrodisplasia Punctata Rizomélica/genética , Condrodisplasia Punctata Rizomélica/patología , Eritrocitos/patologíaRESUMEN
BACKGROUND: Rhizomelic chondrodysplasia punctata (RCDP) is a rare autosomal recessive inherited subtype of a family of congenital anomalies known as chondrodysplasia calcificans punctate (CCP). Given their low rate of occurrence, these cases are highly challenging to diagnose, and because the presence of chondrodysplasia is an indication for legal abortion in Iran, such diagnosis is extremely critical. CASE PRESENTATION: A 27-year-old white multipara was referred for obstetric ultrasonography at 17 weeks and 6 days of gestation because an ultrasonographic study performed at an outside institution revealed a short femur length. Given the patient's positive family history of chondrodysplasia, she underwent targeted sonography to check the anomaly of the bone and cartilage. The key finding in the sonography was short bones for gestational age. CONCLUSION: The important clue in this finding was the patient's family history, which made the gynaecologist request an ultrasound to prevent the birth of a child with a congenital disorder. Genetic tests are usually performed on amniocentesis samples. Because the presence of chondrodysplasia is an indication for legal abortion in Iran, finally, the patient underwent legal abortion after amniocentesis and genetic tests.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Niño , Humanos , Femenino , Embarazo , Adulto , Condrodisplasia Punctata Rizomélica/diagnóstico por imagen , Condrodisplasia Punctata Rizomélica/genética , Diagnóstico Prenatal , Ultrasonografía Prenatal , Ultrasonografía , Pruebas GenéticasRESUMEN
Rhizomelic chondrodysplasia punctata (RCDP) are a group of peroxisomal disorders caused by plasmalogen synthesis defects. Patients with RCDP present with rhizomelic short stature, characteristic punctate epiphyseal calcifications, congenital cataracts, severe intellectual disability, seizures, and facial dysmorphism. Pathogenic variants in AGPS result in RCDP type 3 (RCDP3) which is an extremely rare disorder characterized by isolated ADHAPS deficiency. Six patients with RCDP3 have been identified, upto-date. We report two new patients with RCDP3 and their novel variants, c.154dupG (p.Ala52GlyfsTer6) and c.637+1G>A, in the AGPS gene. We also present a review of previously reported RCDP3 patients.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Condrodisplasia Punctata , Discapacidad Intelectual , Condrodisplasia Punctata/genética , Condrodisplasia Punctata Rizomélica/genética , Condrodisplasia Punctata Rizomélica/patología , Genotipo , Humanos , PlasmalógenosRESUMEN
BACKGROUND: Rhizomelic chondrodysplasia punctata (RCDP) is an inherited ultra-rare disease which results in severely impaired physical and mental development. Mutations in one of five genes involved in plasmalogen biosynthesis have been reported to drive disease pathology. Estimates of disease incidence have been extremely challenging due to the rarity of the disorder, preventing an understanding of the unmet medical need. To address this, we have prepared a disease incidence and prevalence model based on genetic epidemiology approaches to estimate the total number of RCDP patients affected, and their demographic characteristics. RESULTS: Extraction of allelic frequencies for known and predicted pathogenic variants in PEX7, GNPAT, AGPS, FAR1, PEX5 (limited to the PTS2 domain encoding region) genes, from large-scale human genetic diversity datasets (TopMed and gnomAD) revealed the mutational landscape contributing to the RCDP patient population in the US and Europe. We computed genetic prevalence to derive birth incidence for RCDP and modeled the impact to life expectancy to obtain high confidence estimates of disease prevalence. Our population genetics-based model indicates PEX7 variants are expected to contribute to the majority of RCDP cases in both the US and Europe; closely aligning with clinical reports. Furthermore, this model provides estimates for RCDP subtypes due to mutations in other genes, including exceedingly rare subtypes. CONCLUSION: In total, the estimated number of RCDP patients in the US and the five largest European countries (UK, Germany, France, Italy and Spain) is between 516 and 847 patients, all under the age of 35 years old. This model provides a quantitative framework for better understanding the unmet medical need in RCDP, to help guide disease awareness and diagnosis efforts for this specific patient group.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Adulto , Condrodisplasia Punctata Rizomélica/epidemiología , Condrodisplasia Punctata Rizomélica/genética , Europa (Continente) , Francia , Alemania , Humanos , Incidencia , Italia , Epidemiología Molecular , Prevalencia , EspañaRESUMEN
The axon initial segment (AIS) is a specialized region in neurons that encompasses two essential functions, the generation of action potentials and the regulation of the axodendritic polarity. The mechanism controlling the position of the axon initial segment to allow plasticity and regulation of neuron excitability is unclear. Here we demonstrate that plasmalogens, the most abundant ether-phospholipid, are essential for the homeostatic positioning of the AIS. Plasmalogen deficiency is a hallmark of Rhizomelic Chondrodysplasia Punctata (RCDP) and Zellweger spectrum disorders, but Alzheimer's and Parkinson's disease, are also characterized by plasmalogen defects. Neurons lacking plasmalogens displaced the AIS to more distal positions and were characterized by reduced excitability. Treatment with a short-chain alkyl glycerol was able to rescue AIS positioning. Plasmalogen deficiency impaired AKT activation, and we show that inhibition of AKT phosphorylation at Ser473 and Thr308 is sufficient to induce a distal relocation of the AIS. Pathway analysis revealed that downstream of AKT, overtly active ULK1 mediates AIS repositioning. Rescuing the impaired AKT signaling pathway was able to normalize AIS position independently of the biochemical defect. These results unveil a previously unknown mechanism that couples the phospholipid composition of the neuronal membrane to the positional assembly of the AIS.
Asunto(s)
Segmento Inicial del Axón , Homólogo de la Proteína 1 Relacionada con la Autofagia , Condrodisplasia Punctata Rizomélica , Humanos , Péptidos y Proteínas de Señalización Intracelular , Plasmalógenos , Proteínas Proto-Oncogénicas c-akt , Transducción de SeñalRESUMEN
BACKGROUND: Rhizomelic chondrodysplasia punctata (RCDP) is a clinical entity resulting from defects of peroxisomal metabolism whose clinical phenotype is characterized by rhizomelia, calcified foci in periarticular cartilage, coronal lesions of vertebral bodies, cataracts and severe cognitive delay. Usually, survival does not exceed the first decade of life. Transmission is autosomal recessive and is related to mutations in the PEX7, GNPAT or AGPS. METHODS: A detailed description of the prenatal ultrasound signs of RCDP found in two successive pregnancies in a consanguineous couple is reported. Molecular genetic investigations included the study of the coding regions and the exon-intron junctions of the GNPAT (high-throughput amplification and sequencing performed with Roche NimbleGen SeqCap Target kit on Illumina platform); the confirmation test was carried out by amplification and Sanger sequencing with automatic capillary sequencer. RESULTS: In addition to the typical prenatal ultrasound signs described in the literature in association with RCDP, the presence of prefrontal oedema, never previously described, has been detected in both pregnancies. Moreover, genetic investigations have found a new splicing variant c.924+1G>A of the homozygous GNPAT. CONCLUSION: The role of mutation in the GNPAT suggests a likely association with the clinical phenotype.
Asunto(s)
Aciltransferasas/genética , Condrodisplasia Punctata Rizomélica/genética , Adulto , Condrodisplasia Punctata Rizomélica/diagnóstico por imagen , Condrodisplasia Punctata Rizomélica/patología , Femenino , Humanos , Mutación , Empalme del ARN , Ultrasonografía PrenatalAsunto(s)
Anomalías Múltiples/enzimología , Aldehído Oxidorreductasas/deficiencia , Condrodisplasia Punctata Rizomélica/enzimología , Anomalías Múltiples/genética , Condrodisplasia Punctata Rizomélica/genética , Consanguinidad , Femenino , Humanos , Lactante , Mutación Missense , Secuenciación del ExomaRESUMEN
AIMS: Rhizomelic chondrodysplasia punctata (RCDP) is an autosomal recessive inherited disorder. Individuals with RCDP have a wide range of neurodevelopmental outcomes, but there are limited descriptions of their early motor development before 5 months of age. This study aimed to describe in detail the age-specific spontaneous movements and examine the developmental functioning in an individual with RCDP. METHODS: A female infant (born at 39 weeks' gestation), diagnosed with RCDP at 3 weeks of age, was assessed at 4 and 16 weeks for general movements (GMs) and concurrent motor repertoire; the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III) was also applied at the same ages. RESULTS: At 4 weeks, the infant showed poor repertoire GMs, with a detailed General Movement Optimality Score of 16/42. At 16 weeks, age-specific fidgety movements were absent, and the movement character was monotonous and stiff; the detailed Motor Optimality Score was severely reduced (7/28). All Bayley-III scores were <2 SD, that is <70 indicating severe developmental delay. CONCLUSION: Functional assessments such as the GM assessment and age-specific detailed assessment could be complementary to neuroimaging assessments to predict the neurodevelopmental outcomes in infants with RCDP.
Asunto(s)
Condrodisplasia Punctata Rizomélica , Femenino , Edad Gestacional , Humanos , Lactante , Recién Nacido , MovimientoRESUMEN
Rhizomelic chondrodysplasia punctata (RCDP) is a heterogenous group of disorders due to defects in genes encoding peroxisomal proteins required for plasmalogen (PL) biosynthesis, specifically PEX7 and PEX5 receptors, or GNPAT, AGPS and FAR1 enzymes. Most patients have congenital cataract and skeletal dysplasia. In the classic form, there is profound growth restriction and psychomotor delays, with most patients not advancing past infantile developmental milestones. Disease severity correlates to erythrocyte PL levels, which are almost undetectable in severe (classic) RCDP. In milder (nonclassic) forms, residual PL levels are associated with improved growth and development. However, the clinical course of this milder group remains largely unknown as only a few cases were reported. Using as inclusion criteria the ability to communicate and walk, we identified 16 individuals from five countries, ages 5-37 years, and describe their clinical, biochemical and molecular profiles. The average age at diagnosis was 2.6 years and most had cataract, growth deficiency, joint contractures, and developmental delays. Other major symptoms were learning disability (87%), behavioral issues (56%), seizures (43%), and cardiac defects (31%). All patients had decreased C16:0 PL levels that were higher than in classic RCDP, and up to 43% of average controls. Plasma phytanic acid levels were elevated in most patients. There were several common, and four novel, PEX7, and GNPAT hypomorphic alleles in this cohort. These results can be used to support earlier diagnosis and improve management in patients with mild RCDP.
Asunto(s)
Condrodisplasia Punctata Rizomélica/diagnóstico , Estudios de Asociación Genética , Gráficos de Crecimiento , Adolescente , Adulto , Niño , Preescolar , Condrodisplasia Punctata Rizomélica/genética , Femenino , Humanos , Masculino , Adulto JovenRESUMEN
Plasmalogens (Pls) are a class of membrane phospholipids which serve a number of essential biological functions. Deficiency of Pls is associated with common disorders such as Alzheimer's disease or ischemic heart disease. A complete lack of Pls due to genetically determined defective biosynthesis gives rise to rhizomelic chondrodysplasia punctata (RCDP), characterized by a number of severe disabling pathologic features and death in early childhood. Frequent cardiac manifestations of RCDP include septal defects, mitral valve prolapse, and patent ductus arteriosus. In a mouse model of RCDP, reduced nerve conduction velocity was partially rescued by dietary oral supplementation of the Pls precursor batyl alcohol (BA). Here, we examine the impact of Pls deficiency on cardiac impulse conduction in a similar mouse model (Gnpat KO). In-vivo electrocardiographic recordings showed that the duration of the QRS complex was significantly longer in Gnpat KO mice than in age- and sex-matched wild-type animals, indicative of reduced cardiac conduction velocity. Oral supplementation of BA for 2 months resulted in normalization of cardiac Pls levels and of the QRS duration in Gnpat KO mice but not in untreated animals. BA treatment had no effect on the QRS duration in age-matched wild-type mice. These data suggest that Pls deficiency is associated with increased ventricular conduction time which can be rescued by oral BA supplementation.
Asunto(s)
Arritmias Cardíacas/tratamiento farmacológico , Condrodisplasia Punctata Rizomélica/tratamiento farmacológico , Éteres de Glicerilo/farmacología , Plasmalógenos/biosíntesis , Administración Oral , Animales , Arritmias Cardíacas/etiología , Condrodisplasia Punctata Rizomélica/fisiopatología , Suplementos Dietéticos , Modelos Animales de Enfermedad , Electrocardiografía , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Éteres Fosfolípidos/farmacologíaRESUMEN
Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic disorder caused by mutations in peroxisomal genes essential for plasmalogen biosynthesis. Plasmalogens are a class of membrane glycerophospholipids containing a vinyl-ether-linked fatty alcohol at the sn-1 position that affect functions including vesicular transport, membrane protein function and free radical scavenging. A logical rationale for the treatment of RCDP is therefore the therapeutic augmentation of plasmalogens. The objective of this work was to provide a preliminary characterization of a novel vinyl-ether synthetic plasmalogen, PPI-1040, in support of its potential utility as an oral therapeutic option for RCDP. First, wild-type mice were treated with 13C6-labeled PPI-1040, which showed that the sn-1 vinyl-ether and the sn-3 phosphoethanolamine groups remained intact during digestion and absorption. Next, a 4-week treatment of adult plasmalogen-deficient Pex7hypo/null mice with PPI-1040 showed normalization of plasmalogen levels in plasma, and variable increases in plasmalogen levels in erythrocytes and peripheral tissues (liver, small intestine, skeletal muscle and heart). Augmentation was not observed in brain, lung and kidney. Functionally, PPI-1040 treatment normalized the hyperactive behavior observed in the Pex7hypo/null mice as determined by open field test, with a significant inverse correlation between activity and plasma plasmalogen levels. Parallel treatment with an equal amount of ether plasmalogen precursor, PPI-1011, did not effectively augment plasmalogen levels or reduce hyperactivity. Our findings show, for the first time, that a synthetic vinyl-ether plasmalogen is orally bioavailable and can improve plasmalogen levels in an RCDP mouse model. Further exploration of its clinical utility is warranted.This article has an associated First Person interview with the joint first authors of the paper.
Asunto(s)
Condrodisplasia Punctata Rizomélica/tratamiento farmacológico , Plasmalógenos/farmacología , Compuestos de Vinilo/farmacología , Administración Oral , Animales , Disponibilidad Biológica , Condrodisplasia Punctata Rizomélica/fisiopatología , Modelos Animales de Enfermedad , Ácidos Docosahexaenoicos/farmacología , Estabilidad de Medicamentos , Ratones , Ratones Endogámicos C57BL , Actividad Motora/efectos de los fármacos , Receptor de la Señal 2 de Direccionamiento al Peroxisoma/fisiología , Plasmalógenos/química , Plasmalógenos/farmacocinética , Compuestos de Vinilo/química , Compuestos de Vinilo/farmacocinéticaAsunto(s)
Condrodisplasia Punctata Rizomélica/genética , Condrodisplasia Punctata Rizomélica/mortalidad , Niño , Preescolar , Condrodisplasia Punctata Rizomélica/diagnóstico por imagen , Condrodisplasia Punctata Rizomélica/patología , Femenino , Humanos , Lactante , Recién Nacido , Morbilidad , Embarazo , Ultrasonografía PrenatalRESUMEN
The type-2 peroxisomal targeting signal (PTS2) is one of two peptide motifs destining soluble proteins for peroxisomes. This signal acts as amphiphilic α-helix exposing the side chains of all conserved residues to the same side. PTS2 motifs are recognized by a bipartite protein complex consisting of the receptor PEX7 and a co-receptor. Cargo-loaded receptor complexes are translocated across the peroxisomal membrane by a transient pore and inside peroxisomes, cargo proteins are released and processed in many, but not all species. The components of the bipartite receptor are re-exported into the cytosol by a ubiquitin-mediated and ATP-driven export mechanism. Structurally, PTS2 motifs resemble other N-terminal targeting signals, whereas the functional relation to the second peroxisomal targeting signal (PTS1) is unclear. Although only a few PTS2-carrying proteins are known in humans, subjects lacking a functional import mechanism for these proteins suffer from the severe inherited disease rhizomelic chondrodysplasia punctata.
Asunto(s)
Receptor de la Señal 2 de Direccionamiento al Peroxisoma/metabolismo , Secuencias de Aminoácidos , Condrodisplasia Punctata Rizomélica/metabolismo , Condrodisplasia Punctata Rizomélica/patología , Humanos , Proteínas de la Membrana/metabolismo , Receptor de la Señal 2 de Direccionamiento al Peroxisoma/química , Receptor de la Señal 2 de Direccionamiento al Peroxisoma/genética , Peroxisomas/metabolismo , Dominios Proteicos , Estructura Cuaternaria de Proteína , Transporte de ProteínasRESUMEN
BACKGROUND: Cervical spine deformity in rhizomelic chondrodysplasia punctata (RCDP) has been described with different findings reported in the literature. However, available literature provides limited data from a few cases with magnetic resonance imaging (MRI) of the cervical spine. Our report describes the MRI findings in a group of children with RCDP, aiming to reach a better understanding of this pathology. METHODS: An Institutional Review Board-approved RCDP Registry was created at our institution with the goal of identifying pertinent medical issues over the lifespan of individuals with RCDP. Records of children within the registry were evaluated, and magnetic resonance images obtained between 2004 and 2015, were available for review. The levels of spinal canal stenosis were recorded and the severity of the stenosis was decided based on adults' parameters. Cord compression and myelomalacia were confirmed on the axial images. Sagittal lumbar spine magnetic resonance images were also evaluated when available, and the presence of tethered cord and fatty filum was recorded. RESULTS: Twenty-six children (15 boys and 11 girls) were identified in the RCDP Registry. Eleven children (6 boys and 5 girls) had sagittal MRI of the cervical spine available for review. Age at the time of MRI study was variable (1 wk to 32 mo). All patients except 1 had stenosis of the cervical spinal canal. Myelomalacia of the cord was noted only in this patient. CONCLUSIONS: This study suggests that, in children with RCDP, cervical spinal stenosis and cord compression are a real risk, and children with this diagnosis should have monitoring for these issues. Tethered cord is also a possible finding that needs to be evaluated. Full sagittal spine MRI is necessary to detect the possible deformities at the cervical and lumbar levels.
Asunto(s)
Vértebras Cervicales/patología , Condrodisplasia Punctata Rizomélica/complicaciones , Compresión de la Médula Espinal/etiología , Estenosis Espinal/etiología , Vértebras Cervicales/diagnóstico por imagen , Preescolar , Condrodisplasia Punctata Rizomélica/diagnóstico por imagen , Condrodisplasia Punctata Rizomélica/patología , Constricción Patológica , Femenino , Humanos , Lactante , Vértebras Lumbares/diagnóstico por imagen , Vértebras Lumbares/patología , Imagen por Resonancia Magnética , Masculino , Canal Medular/diagnóstico por imagen , Canal Medular/patología , Compresión de la Médula Espinal/diagnóstico por imagen , Compresión de la Médula Espinal/patología , Enfermedades de la Médula Espinal , Estenosis Espinal/diagnóstico por imagen , Estenosis Espinal/patologíaRESUMEN
Plasmalogens are the most abundant form of ether phospholipids in myelin and their deficiency causes Rhizomelic Chondrodysplasia Punctata (RCDP), a severe developmental disorder. Using the Gnpat-knockout (KO) mouse as a model of RCDP, we determined the consequences of a plasmalogen deficiency during myelination and myelin homeostasis in the central nervous system (CNS). We unraveled that the lack of plasmalogens causes a generalized hypomyelination in several CNS regions including the optic nerve, corpus callosum and spinal cord. The defect in myelin content evolved to a progressive demyelination concomitant with generalized astrocytosis and white matter-selective microgliosis. Oligodendrocyte precursor cells (OPC) and mature oligodendrocytes were abundant in the CNS of Gnpat KO mice during the active period of demyelination. Axonal loss was minimal in plasmalogen-deficient mice, although axonal damage was observed in spinal cords from aged Gnpat KO mice. Characterization of the plasmalogen-deficient myelin identified myelin basic protein and septin 7 as early markers of dysmyelination, whereas myelin-associated glycoprotein was associated with the active demyelination phase. Using in vitro myelination assays, we unraveled that the intrinsic capacity of oligodendrocytes to ensheath and initiate membrane wrapping requires plasmalogens. The defect in plasmalogens was rescued with glyceryl 1-myristyl ether [1-O-tetradecyl glycerol (1-O-TDG)], a novel alternative precursor in the plasmalogen biosynthesis pathway. 1-O-TDG treatment rescued myelination in plasmalogen-deficient oligodendrocytes and in mutant mice. Our results demonstrate the importance of plasmalogens for oligodendrocyte function and myelin assembly, and identified a novel strategy to promote myelination in nervous tissue.
Asunto(s)
Éteres de Glicerilo/farmacología , Oligodendroglía/metabolismo , Plasmalógenos/metabolismo , Animales , Axones/metabolismo , Sistema Nervioso Central/metabolismo , Condrodisplasia Punctata Rizomélica/metabolismo , Enfermedades Desmielinizantes , Modelos Animales de Enfermedad , Leucodistrofia Metacromática/fisiopatología , Ratones , Ratones Noqueados , Vaina de Mielina/metabolismo , Vaina de Mielina/fisiología , Oligodendroglía/fisiología , Peroxisomas , Médula Espinal/metabolismoAsunto(s)
Calcinosis/diagnóstico , Condrodisplasia Punctata Rizomélica/complicaciones , Epífisis/diagnóstico por imagen , Húmero/diagnóstico por imagen , Calcinosis/etiología , Condrodisplasia Punctata Rizomélica/diagnóstico , Diagnóstico Diferencial , Femenino , Pruebas Genéticas , Humanos , Recién Nacido , Receptor de la Señal 2 de Direccionamiento al Peroxisoma/deficiencia , RadiografíaRESUMEN
Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic peroxisome biogenesis disorder with a reported incidence of 1 in 100 000 live births. The 3 genetic subtypes of RCDP are acquired by an autosomal recessive inheritance pattern. RCDP type 1 accounts for greater than 90% of all aggregate cases. Differentiating between the 3 subtypes of RCDP, as well as disorders characterized by similar punctate cartilaginous changes, is essential to guide an appropriate postnatal plan of care. Management strategies are focused toward associated clinical manifestations and require an interdisciplinary approach including ophthalmology, cardiovascular, endocrine, physical and occupational therapy, and neurology. Purposeful and frequent collaboration among all members of the neonatal/pediatric interdisciplinary team is necessary to optimize outcomes for the neonate and the family unit. The purpose of this article is to anticipate the needs of both patients with known and prenatal diagnosis of RCDP type 1 and patients with suspected clinical diagnosis of RCDP type 1 in the immediate neonatal period and to guide the appropriate plan of care. This article presents a case report of type I RCDP, as well as describes genetic influences, symptoms, diagnosis, management, and prognosis.
Asunto(s)
Condrodisplasia Punctata Rizomélica/genética , Condrodisplasia Punctata Rizomélica/terapia , Predisposición Genética a la Enfermedad , Adulto , Puntaje de Apgar , Cesárea , Condrodisplasia Punctata Rizomélica/diagnóstico por imagen , Terapia Combinada , Femenino , Humanos , Recién Nacido , Masculino , Receptor de la Señal 2 de Direccionamiento al Peroxisoma/deficiencia , Embarazo , Diagnóstico Prenatal , PronósticoRESUMEN
INTRODUCTION: Peroxisomal diseases are a group of monogenic disorders that include defects in peroxisome biogenesis or enzyme dificiencies. Rhizomelic chondrodysplasia punctata type 1 (RCDP1) belongs to the first group, caused by autosomal recessive mutations on PEX7 gene, encoding for PTS2 receptor. The aims of this report are to describe a genetic disease of low prevalence, explaining its main characteristics and the importance of the diagnostic approach and genetic counseling. CASE REPORT: 13-month-old male infant with no medical history, family or consanguinity, demonstrate at birth upper limbs shortening. Surgery intervention at seven months old for bilateral cataract. Growth retardation, psychomotor retardation, minor craniofacial anomalies, rhyzomelic shortened upper limbs and lower limbs lesser degree. Punctata calcifications in patella cartilage. Also fatty acid phytanic and pristanic increased levels. Patient dead at age of 3 years. DISCUSSION: RCDP1 is a rare disease, with a prevalence of 1/100,000. Different mutations of PEX7 gene have been described, with variations in phenotype. The treatment is basically symptomatic and depends on the severity of clinical manifestations. The rhizomelic type has poor prognosis, most patients do not survive before the first decade of live. Genetic counseling is essential because it is consider a 25% risk of recurrence.